NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
Clinical Trials
15 trialsNCT06097728 2026-04-02
eVOLVE-Meso
AstraZeneca
Phase 3 Recruiting
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT04334759 2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3 Completed
NCT04400539 2025-09-25
IMPALA
University Hospital, Lille
Phase 2 Recruiting
NCT04162015 2025-09-12
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03907852 2025-08-27
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
Phase 1/2 Active not recruiting
NCT04040231 2025-05-13
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04177953 2025-02-06
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04300244 2024-02-29
NIPU
Oslo University Hospital
Phase 2 Active not recruiting
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT04013334 2022-06-16
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Momotaro-Gene Inc.
Phase 2 Unknown
NCT03048474 2021-01-20
INITIATE
The Netherlands Cancer Institute
Phase 2 Completed
NCT02497508 2017-09-14
NivoMes
The Netherlands Cancer Institute
Phase 2 Completed